BRIEF published on 04/09/2025 at 07:35, 1 year 5 months ago Bluelinea : Résultats annuels 2024 et chiffre d'affaires T1 2025 Résultats Financiers EBITDA Croissance Trimestrielle Soutien Financier Offre SERENEA
BRIEF published on 04/09/2025 at 07:35, 1 year 5 months ago Bluelinea: 2024 annual results and Q1 2025 revenue Financial Results EBITDA Financial Support Quarterly Growth Serenea Offer
BRIEF published on 04/09/2025 at 07:35, 1 year 5 months ago OSE Immunotherapeutics to Present Data on Lusvertikimab at DDW 2025 Ulcerative Colitis OSE Immunotherapeutics Lusvertikimab Phase 2 Extension DDW 2025
BRIEF published on 04/09/2025 at 07:35, 1 year 5 months ago OSE Immunotherapeutics présentera des données sur le lusvertikimab au DDW 2025 Rectocolite Hémorragique OSE Immunotherapeutics Lusvertikimab DDW 2025 Extension De La Phase 2
BRIEF published on 04/09/2025 at 07:06, 1 year 5 months ago Leonteq AG Enters Swiss Market for Leverage Products Leonteq AG Swiss Market Technology Platform Strategic Expansion Leverage Products
BRIEF published on 04/09/2025 at 07:06, 1 year 5 months ago Leonteq AG entre sur le marché suisse des produits à effet de levier Leonteq AG Marché Suisse Plateforme Technologique Expansion Stratégique Produits À Effet De Levier
BRIEF published on 04/09/2025 at 07:05, 1 year 5 months ago ARYZTA AG Invites Stakeholders to Upcoming AGM Corporate Governance SIX Swiss Exchange ARYZTA AG Convenience Bakery AGM 2025
BRIEF published on 04/09/2025 at 07:05, 1 year 5 months ago ARYZTA AG invite les parties prenantes à sa prochaine assemblée générale annuelle Gouvernance D'Entreprise SIX Swiss Exchange ARYZTA AG Boulangerie De Proximité Assemblée Générale Annuelle 2025
BRIEF published on 04/09/2025 at 07:05, 1 year 5 months ago Biophytis lance la phase 2 de l'essai clinique OBA pour l'obésité Investissement Biophytis Essai Clinique BIO101 Obésité
BRIEF published on 04/09/2025 at 07:05, 1 year 5 months ago Biophytis Initiates Phase 2 OBA Clinical Trial for Obesity Treatment Biophytis Obesity Treatment Clinical Trial BIO101 Partnership Goal
Published on 09/12/2026 at 02:35, 16 hours 13 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 19 hours 48 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 20 hours 43 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 21 hours 23 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 1 hour ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 57 minutes ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 11 hours 17 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 20 hours 32 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 20 hours 37 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 23 hours 3 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 1 day 11 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 11 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 23 hours ago Availability of the 2026 Interim Financial Report
